| SOLV |
Report |
Adj. diluted EPS (Q2) |
BEAT |
pred ~$2.05 vs. cons $1.91 |
HIGH |
| SOLV |
Report |
Net sales (Q2, reported) |
BEAT |
pred ~$2.24B vs. cons $2.17B |
HIGH |
| SOLV |
Report |
Adj. operating margin (Q2) |
BEAT |
pred ~22.7% vs. cons ~21.6% |
MEDIUM |
| SOLV |
Guide |
FY26 Adj. EPS guide |
BETTER |
guide ~$6.55-6.65 (raised, top-end/above) vs. cons ~$6.53 (FY26) |
MEDIUM |
| SOLV |
Guide |
FY26 organic sales growth guide |
UNCHANGED |
guide ~+2.0-3.0% vs. cons ~+2.8% (FY26) |
MEDIUM |
| SOLV |
Guide |
Advance-order pull-forward magnitude (H2/Q3 offset) |
UNKNOWN |
pred ~$100-130M pulled into Q2, offset out of H2 vs. cons ~$100M framing (FY26 phasing) |
LOW |
| SOLV |
Guide |
FY26 free cash flow guide |
UNCHANGED |
guide ~$200M (H2/Q4-weighted) vs. cons ~$200M (FY26) |
LOW |
| SOLV |
Guide |
Q2 buyback pace |
BETTER |
pred ~$150-250M repurchased vs. ~$67M prior-Q run-rate (Q2, $1B auth live) |
LOW |
| SOLV |
Return |
Day-1 residual (stock − beta × S&P 500) |
-2.5% |
— |
LOW |
| SOLV |
Return |
5-day cumulative residual |
-4.0% (FADE) |
Headline Q2 beat is largely mechanical (>$100M advance-order pull-forward dropping ~30% to EPS) with a matching H2/Q3 reversal, so out-period math forces Q3/H2 estimate cuts even as FY26 is only reaffirmed-to-slightly-raised. With shares +~40% off March lows and pinned at 52-wk highs (~$88) after the UBS upgrade, the bar is high and the print quality (timing vs. real demand) gets scrutinized — a clean-but-non-recurring beat sets up sell-the-news, and downward Q3 revisions extend the fade over the week absent a demand-driven guide raise. |
LOW |